



EHA 2023 abstracts:

What's hot in acute lymphoblastic leukemia?

To help navigate the exciting content being presented at the EHA2023 Congress, the ALL Hub Steering Committee have provided their recommendations of the top abstracts to look for in ALL.



Click
the abstracts
to view

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://lymphomahub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.



Scientific Education Support

Frontline and emerging therapies

S112	<u>The effect of immunoglobulin prophylaxis on infectious morbidity in pediatric patients with acute lymphoblastic leukemia: results of a randomized controlled trial</u>
S116	<u>Donor-derived CD5 CAR T cells for T-cell acute lymphoblastic leukemia</u>
S117	<u>Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: ALLIANCE A041703</u>
S118	<u>A chemotherapy-free combination of ponatinib and blinatumomab for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: subgroup analysis from a phase II study</u>
P329	<u>High immunoproteasome activity as novel indicator for sensitivity to bortezomib-containing chemotherapy in acute lymphoblastic leukemia patients from Children's Oncology Group trial AALL1231</u>
P355	<u>Favorable outcome of Philadelphia-positive acute lymphoblastic leukemia with imatinib, dose-reduced induction followed by allogeneic stem cell transplantation –results from the GMALL trial 08/13</u>
P358	<u>Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a phase II study</u>
P364	<u>A phase II study of low-intensity chemotherapy (mini-hyper-CVD) and ponatinib followed by blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia</u>
P365	<u>Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed Ph- B-precursor acute lymphoblastic leukemia – final results of the ALLG ALL08 study</u>
P373	<u>Updates from a phase II trial of mini-hyper-CVD-inotuzumab with or without blinatumomab in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia</u>
P376	<u>Veno-occlusive disease risk and other outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin and proceeding to hematopoietic stem cell transplantation</u>
P390	<u>Allo-HSCT or chemotherapy for B-cell acute lymphoblastic leukemia in the first complete remission: Impact of MRD and <i>IKZF1</i></u>
P394	<u>Frontline combination of olverembatinib and PDT-ALL-2016 pediatric inspired protocol in Philadelphia chromosome-positive acute lymphoblastic leukemia</u>
P397	<u><i>IKZF1</i> alterations have a negative impact on early molecular response and survival of adult patients with B-cell precursor acute lymphoblastic leukemia treated with GMALL 07/2003 protocol in Czechia</u>

Treatment for relapsed/refractory ALL

S113	<u>Impact of <i>IKZF1</i> deletion in relapsed and/or refractory B-cell acute lymphoblastic leukemia treated with CD19-chimeric antigen receptor T-cell therapy</u>
S115	<u>Consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and MRD level in ECOG-ACRIN E1910</u>
S119	<u>Combination of mini-hyper-CVD and inotuzumab (INO) followed by blinatumomab (BLINA) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A phase II trial</u>
S312	<u>Is brexucabtagene autoleucel a cost-effective treatment for refractory/relapsed acute lymphoblastic leukemia? A pharmacoeconomic analysis in the perspective of the public healthcare system.</u>
P336	<u>Predictive scores for relapse and progression disease in pediatric acute lymphoblastic leukemia patients based on optical genome mapping technology</u>
P348	<u>Genomic characterization of relapsed/refractory B-cell acute lymphoblastic leukemia pediatric patients undergoing CAR-T treatment in a single center</u>
P362	<u>Outcomes in patients with relapsed or refractory acute lymphoblastic leukemia receiving hematopoietic cell transplantation using real-world data from HARMONY</u>
P363	<u>A phase II study of flumatinib with chemotherapy for newly diagnosed Ph/<i>BCR-ABL1</i>-positive acute lymphoblastic leukemia in adults: updated results from RJ-ALL2020.2A trial</u>
P367	<u>Long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 by age, prior therapies, and subsequent transplant</u>
P370	<u>Efficacy and safety of the third-generation TKI olverembatinib in adults Ph/<i>BCR-ABL1</i>-positive acute lymphoblastic leukemia with <i>T315I</i> mutation and relapsed/refractory disease</u>
P377	<u>A phase II trial of mini-hyper-CVD with venetoclax for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL)</u>
P379	<u>Ponatinib and blinatumomab in relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase: subgroup analysis from a phase II trial</u>
P501	<u>Isatuximab plus chemotherapy for pediatric relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): Interim efficacy analysis</u>



Biomarkers and biology

S105	<u>Clonal differentiation trajectories of adult acute lymphoblastic leukemia at single cell level</u>
P319	<u>IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition</u>
P321	<u>TNF-mediated cell death: an actionable target for immunotherapy in T-cell Acute Lymphoblastic Leukemia</u>
P331	<u>The oncogenic transcription factor TCF3::HLF marks a distinct enhancer-promoter interaction network in T(17;19) positive childhood acute lymphoblastic leukemia</u>
P393	<u>Genetic characteristics of pediatric B-other acute lymphoblastic leukemia cohort using targeted RNA sequencing</u>
P403	<u>High expression of STAT5 indicates poor prognosis in B cell acute lymphoblastic leukemia</u>

Real-world evidence

P401	<u>Innovative reduced-dose chemotherapy followed by blinatumomab induction therapy for successful management of treatment naive B-cell acute lymphoblastic leukemia adults: A multicenter, real-world study</u>
P402	<u>Inotuzumab ozogamicin treatment in adult patients with relapsed or refractory Philadelphia chromosome-negative CD22-positive B-cell precursor acute lymphoblastic leukemia: A real-life French study</u>





Follow us on Twitter to keep up to date
with the latest from the EHA2023 Congress.

**@ALL_Hub_
#EHA2023
lymphoblastic-hub.com**